KU Hematology & Medical Oncology Review 2019

 

KU Hematology & Medical Oncology Review 2019
C

KU ASCO 2019 Review of SCLC, Early & Locally Advanced NSCLC: Year of Neoadjuvant Therapy and Checkpoint Inhibitors

By KU Hematology & Medical Oncology Review 2019 FEATURING Corey Langer
By KU Hematology & Medical Oncology Review 2019 FEATURING Corey Langer
0 views
August 2, 2019
Comments 1
Login to view comments. Click here to Login

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy

Featured Video

02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy
Lung
15:47
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Review of SCLC, Early & Locally Advanced NSCLC: Yea…

Feat. C. Langer
22:33
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Review of Recurrent / Metastatic NSCLC: Wild Type, KN00…

Feat. C. Langer